Table 3.
Univariate analyses of factors potentially associated with response to brentuximab vedotin
| Factor | Objective response* |
PFS |
||||
|---|---|---|---|---|---|---|
| Odds ratio | 95% CI | P | Hazard ratio | 95% CI | P | |
| Total no. of prior regimens† | 1.07 | 0.87-1.32 | .54 | 0.96 | 0.82-1.13 | .65 |
| Prior autoSCT, yes/no | 0.90 | 0.14-5.65 | .91 | 2.75 | 0.57-13.23 | .21 |
| Prior DLI, yes/no | 2.75 | 0.40-18.87 | .30 | 0.53 | 0.11-2.50 | .42 |
| Prior external beam radiation, yes/no | 2.00 | 0.16-25.40 | .59 | 0.98 | 0.21-4.66 | .98 |
| No. of prior systemic chemotherapy regimens | 1.01 | 0.76-1.33 | .96 | 0.97 | 0.78-1.19 | .74 |
| AlloSCT | ||||||
| Donor source | ||||||
| Matched, related | 4.67 | 0.40-53.95 | .42 | 0.62 | 0.12-3.31 | .58 |
| Matched, unrelated | 5.33 | 0.38-75.77 | .36 | 0.77 | 0.13-4.52 | .77 |
| Other | Ref. | Ref. | Ref. | Ref. | ||
| Time to disease progression, < 6 mo vs ≥ 6 mo | 0.60 | 0.10-3.50 | .57 | 2.68 | 0.56-12.87 | .22 |
| No. of regimens in the interval between alloSCT and brentuximab vedotin† | 1.05 | 0.85-1.28 | .67 | 0.98 | 0.83-1.15 | .77 |
| Most recent regimen†‡ | ||||||
| Objective response, yes/no | 0.61 | 0.13-2.98 | .54 | 0.50 | 0.13-1.97 | .32 |
| Time to disease progression, < 6 mo vs ≥ 6 mo | 1.13 | 0.20-6.05 | .89 | 1.20 | 0.29-4.95 | .80 |
| Any prior GVHD, yes/no | 0.89 | 0.17-4.78 | .89 | 1.28 | 0.36-4.52 | .70 |
95% CI indicates 95% confidence interval.
*
Objective response was evaluated using logistical regression and PFS was evaluated using Cox regression. Two-sided P values are presented.
†
Includes autoSCT, alloSCT, DLI, systemic chemotherapy, and external beam radiation. Conditioning therapy for SCT is not counted as a separate regimen.
‡
Most recent regimen prior to initiation of brentuximab vedotin therapy.